ProCE Banner Activity

Phase I/II Study of Anti‒CSF-1R Antibody Axatilimab in Heavily Pretreated Chronic Graft-vs-Host Disease

Slideset Download
Conference Coverage
In patients with heavily pretreated chronic GVHD, axatilimab showed promising clinical activity with symptom improvement and acceptable safety.

Released: December 22, 2021

Expiration: December 21, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation